Brisbane, Calif.-based VaxGen has opened an $11-million facility in South San Francisco that will manufacture the company’s anthrax vaccine, AIDS vaccine, and products ranging from smallpox vaccine to monoclonal antibodies. The 17,000-sf facility is adjacent to the company’s research and development operations, and features stainless steel bioprocessors and purifiers. The facility can be easily reconfigured as manufacturing requirements change as much of the equipment is on wheels.
With potential expansion space of 30,000 sf wil enable VaxGen to expand its capabilities in the future. VaxGen is also involved in a joint venture, Celltrion Inc., which is constructing a 23-acre biologics manufacturing facility in Incheon, South Korea. The South San Francisco facility will also be used to train workers for the plant in Incheon.
